BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...which is led by former University College London researcher Philip Beales as CEO, was partially funded by UCL...
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

...of immuno-oncology play NovalGen Ltd., is now CEO of the company. He is a professor of immunology at University College London...
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...million), with Syncona investing £25.3 million in the new tranche for a 74% stake and UCL...
...in 2019.Syncona launched the company in 2019 in partnership with six founders from King’s College London, University College London (UCL...
...ALS).COMPANY PROFILEQuell Therapeutics Ltd.London, U.K.Technology: CAR Treg cell therapy platformOrigin of technology: King’s College London, University College London...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London...
...protein SARS-CoV-2 S – SARS-CoV-2 spike protein Danielle Golovin RG6292, RO7296682 University College London Immune-Onc...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

...solid tumors.CSF, plasma biomarker for spinocerebellar ataxia type 3A team led by Mayo Clinic and University College London...
...North Carolina at Chapel Hill Asklepios BioPharmaceutical Inc. Pacylex Pharmaceuticals University of Alberta Kronos Bio Inc. Massachusetts Institute of Technology Mayo Clinic University College London Ohana...
BioCentury | Aug 28, 2020
Distillery Therapeutics

CRISPR-based gene editing for Wiskott-Aldrich syndrome

...Rai, R. et al. Nat. Commun.; published online Aug. 12, 2020doi:10.1038/s41467-020-17626-2CONTACT: Alessia Cavazza, University College London, London, U.K.email: a.cavazza@ucl.ac.uk Claire Quang University College London Wiskott-Aldrich...
BioCentury | Aug 21, 2020
Product Development

Merck’s north London pick for discovery center could accelerate growth of surrounding research hub

...it the largest single biomedical research laboratory in Europe.In all, the area includes seven universities, including University College London; 59...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...£25 million in an initial 2015 round; Syncona provided almost all of that cash, with UCL...
BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

...partners: None Number of employees: 5 Funds raised: $10 million Investors: ASLA Ventures, Epidarex Capital, UCL...
BioCentury | May 5, 2020
Deals

BioMarin builds on gene therapy momentum with DiNAQOR deal in cardiomyopathy

...BioMarin’s BD BioMarin had experience working with DiNAQOR’s leadership team via academic collaborations with the University College London...
Items per page:
1 - 10 of 356
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...which is led by former University College London researcher Philip Beales as CEO, was partially funded by UCL...
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

...of immuno-oncology play NovalGen Ltd., is now CEO of the company. He is a professor of immunology at University College London...
BioCentury | Feb 12, 2021
Emerging Company Profile

Quell: tweaking Tregs for persistence, potency and stability

...million), with Syncona investing £25.3 million in the new tranche for a 74% stake and UCL...
...in 2019.Syncona launched the company in 2019 in partnership with six founders from King’s College London, University College London (UCL...
...ALS).COMPANY PROFILEQuell Therapeutics Ltd.London, U.K.Technology: CAR Treg cell therapy platformOrigin of technology: King’s College London, University College London...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

...depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London...
...protein SARS-CoV-2 S – SARS-CoV-2 spike protein Danielle Golovin RG6292, RO7296682 University College London Immune-Onc...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

...solid tumors.CSF, plasma biomarker for spinocerebellar ataxia type 3A team led by Mayo Clinic and University College London...
...North Carolina at Chapel Hill Asklepios BioPharmaceutical Inc. Pacylex Pharmaceuticals University of Alberta Kronos Bio Inc. Massachusetts Institute of Technology Mayo Clinic University College London Ohana...
BioCentury | Aug 28, 2020
Distillery Therapeutics

CRISPR-based gene editing for Wiskott-Aldrich syndrome

...Rai, R. et al. Nat. Commun.; published online Aug. 12, 2020doi:10.1038/s41467-020-17626-2CONTACT: Alessia Cavazza, University College London, London, U.K.email: a.cavazza@ucl.ac.uk Claire Quang University College London Wiskott-Aldrich...
BioCentury | Aug 21, 2020
Product Development

Merck’s north London pick for discovery center could accelerate growth of surrounding research hub

...it the largest single biomedical research laboratory in Europe.In all, the area includes seven universities, including University College London; 59...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...£25 million in an initial 2015 round; Syncona provided almost all of that cash, with UCL...
BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

...partners: None Number of employees: 5 Funds raised: $10 million Investors: ASLA Ventures, Epidarex Capital, UCL...
BioCentury | May 5, 2020
Deals

BioMarin builds on gene therapy momentum with DiNAQOR deal in cardiomyopathy

...BioMarin’s BD BioMarin had experience working with DiNAQOR’s leadership team via academic collaborations with the University College London...
Items per page:
1 - 10 of 356